IV Relenza saves U.K. woman from H1N1 flu

Mainlining GlaxoSmithKline's Relenza could end up as the swine-flu treatment of last resort. British doctors saved the life of a woman with severe H1N1 flu, using an unapproved IV form of the Glaxo antiviral. Report

Suggested Articles

The eight-year deal will initially cover lupus drug Benlysta and could expand to other GSK specialty-care products in the future.

Amarin had big plans for Vascepa after a big label expansion last year, but it lost a patent fight—and now a generic has won FDA approval.

Intercept Pharmaceuticals, eager to market its potential nonalcoholic steatohepatitis medicine obeticholic acid, will have to keep waiting.